CG Oncology Inc. (CGON)
NASDAQ • Healthcare
Last close at October 2, 2026 at 20:00 UTC
Metrics Over Time
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 13
in 40 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
CG Oncology’s second fiscal quarter of 2026 earnings trailed consensus, with EPS of -$0.90 versus an estimate of -$0.66 (difference -$0.24), as it reported results on August 6, 2026. Revenue came in at about $1.2 million, while operating income was a loss of roughly $86 million, reflecting spending tied to its clinical-stage focus on cretostimogene. Net income was a loss of about $79 million, down ~91% from roughly $41 million a year ago, and EPS of -$0.90 compared with -$0.54 in the year-ago quarter (YoY change -66.7%). For the next period, consensus calls for EPS of -$0.67.
About CG Oncology Inc.
CG Oncology Inc. is a U.S. biotechnology company listed on NASDAQ under the ticker CGON that develops bladder-cancer therapies. In qualitative terms, it is a clinical-stage healthcare business centered on cretostimogene grenadenorepvec, also referred to as cretostimogene, an investigational oncolytic immunotherapy.
Today's Snapshot
The day ended with CGON 1.4% lower at 67.38, while its sector was flat.
Trading Volume
Above 10d avg 1.3M
1.5M
vs S&P 500 Today
Underperforming Market
-2.20%
Updated: October 2, 2026 at 20:02 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$62.95 - $72.50Sell
- RSI (14)38.57Neutral
- Stochastic %K (14, 3, 3)19.59Buy
- MACD Level (12, 26)-1.57Sell
Peers & Related Assets
Get premium market insights delivered directly to your inbox.